Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Pat...
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
About this item
Full title
Author / Creator
Publisher
Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs).
Patients in IMbrave150 who were randomized to a...
Alternative Titles
Full title
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6af5eea42a484415bfabf884579086db
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6af5eea42a484415bfabf884579086db
Other Identifiers
ISSN
2235-1795
E-ISSN
1664-5553
DOI
10.1159/000535501
